-
Je něco špatně v tomto záznamu ?
Transport mechanisms of a novel antileukemic and antiviral compound 9-norbornyl-6-chloropurine
P. Plačková, H. Hřebabecký, M. Šála, R. Nencka, T. Elbert, H. Mertlíková-Kaiserová,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Taylor & Francis Open Access
od 2002-01-01
Medline Complete (EBSCOhost)
od 2007-02-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- ABC transportéry antagonisté a inhibitory genetika metabolismus MeSH
- antitumorózní látky chemická syntéza metabolismus farmakologie MeSH
- biologický transport MeSH
- buthionin sulfoximin farmakologie MeSH
- chinoliny farmakologie MeSH
- dibenzocyklohepteny farmakologie MeSH
- exprese genu MeSH
- kinetika MeSH
- kyselina ethakrynová farmakologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- permeabilita buněčné membrány účinky léků MeSH
- propionáty farmakologie MeSH
- puriny chemická syntéza metabolismus farmakologie MeSH
- T-lymfocyty účinky léků metabolismus patologie MeSH
- tritium MeSH
- usnadněná difuze MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
6-Chloropurines substituted at the position 9 with variously modified bicyclic skeletons represent promising antiviral and anticancer agents. This work aimed to investigate the transport mechanisms of 9-[(1R*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9H-purine (9-norbornyl-6-chloropurine, NCP) and their relationship to the metabolism and biological activity of the compound. Transport experiments were conducted in CCRF-CEM cells using radiolabeled compound ([(3)H]NCP). The pattern of the intracellular uptake of [(3)H]NCP in CCRF-CEM cells pointed to a combination of passive and facilitated diffusion as prevailing transport mechanisms. NCP intracellular metabolism was found to enhance its uptake by modifying NCP concentration gradient. The transport kinetics reached steady state under the conditions of MRP and MDR proteins blockade, indicating that NCP is a substrate for these efflux pumps. Their inhibition also increased the cytotoxicity of NCP. Our findings suggest that the novel nucleoside analog NCP has potential to become a new orally available antileukemic agent due to its rapid membrane permeation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15032048
- 003
- CZ-PrNML
- 005
- 20170313083402.0
- 007
- ta
- 008
- 151005s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/14756366.2013.879576 $2 doi
- 035 __
- $a (PubMed)24679051
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Plačková, Pavla $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic , Prague , Czech Republic.
- 245 10
- $a Transport mechanisms of a novel antileukemic and antiviral compound 9-norbornyl-6-chloropurine / $c P. Plačková, H. Hřebabecký, M. Šála, R. Nencka, T. Elbert, H. Mertlíková-Kaiserová,
- 520 9_
- $a 6-Chloropurines substituted at the position 9 with variously modified bicyclic skeletons represent promising antiviral and anticancer agents. This work aimed to investigate the transport mechanisms of 9-[(1R*,2R*,4S*)-bicyclo[2.2.1]hept-2-yl]-6-chloro-9H-purine (9-norbornyl-6-chloropurine, NCP) and their relationship to the metabolism and biological activity of the compound. Transport experiments were conducted in CCRF-CEM cells using radiolabeled compound ([(3)H]NCP). The pattern of the intracellular uptake of [(3)H]NCP in CCRF-CEM cells pointed to a combination of passive and facilitated diffusion as prevailing transport mechanisms. NCP intracellular metabolism was found to enhance its uptake by modifying NCP concentration gradient. The transport kinetics reached steady state under the conditions of MRP and MDR proteins blockade, indicating that NCP is a substrate for these efflux pumps. Their inhibition also increased the cytotoxicity of NCP. Our findings suggest that the novel nucleoside analog NCP has potential to become a new orally available antileukemic agent due to its rapid membrane permeation.
- 650 _2
- $a ABC transportéry $x antagonisté a inhibitory $x genetika $x metabolismus $7 D018528
- 650 _2
- $a antitumorózní látky $x chemická syntéza $x metabolismus $x farmakologie $7 D000970
- 650 _2
- $a biologický transport $7 D001692
- 650 _2
- $a buthionin sulfoximin $x farmakologie $7 D019328
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a permeabilita buněčné membrány $x účinky léků $7 D002463
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a dibenzocyklohepteny $x farmakologie $7 D003986
- 650 _2
- $a kyselina ethakrynová $x farmakologie $7 D004976
- 650 _2
- $a usnadněná difuze $7 D055459
- 650 _2
- $a exprese genu $7 D015870
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a propionáty $x farmakologie $7 D011422
- 650 _2
- $a puriny $x chemická syntéza $x metabolismus $x farmakologie $7 D011687
- 650 _2
- $a chinoliny $x farmakologie $7 D011804
- 650 _2
- $a T-lymfocyty $x účinky léků $x metabolismus $x patologie $7 D013601
- 650 _2
- $a tritium $7 D014316
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hřebabecký, Hubert
- 700 1_
- $a Šála, Michal $7 xx0211643
- 700 1_
- $a Nencka, Radim
- 700 1_
- $a Elbert, Tomáš
- 700 1_
- $a Mertlíková-Kaiserová, Helena
- 773 0_
- $w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 30, č. 1 (2015), s. 57-62
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24679051 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20170313083622 $b ABA008
- 999 __
- $a ok $b bmc $g 1092924 $s 915174
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 30 $c 1 $d 57-62 $e 20140331 $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
- LZP __
- $a Pubmed-20151005